Postmenopausal hormone therapy and cognition: Effects of timing and treatment type

Khoo, S. K., O'Neill, S., Byrne, G., King, R., Travers, C. and Tripcony, L. (2010) Postmenopausal hormone therapy and cognition: Effects of timing and treatment type. Climacteric, 13 3: 259-264. doi:10.3109/13697130903370316


Author Khoo, S. K.
O'Neill, S.
Byrne, G.
King, R.
Travers, C.
Tripcony, L.
Title Postmenopausal hormone therapy and cognition: Effects of timing and treatment type
Journal name Climacteric   Check publisher's open access policy
ISSN 1369-7137
1473-0804
Publication date 2010-06
Year available 2009
Sub-type Article (original research)
DOI 10.3109/13697130903370316
Volume 13
Issue 3
Start page 259
End page 264
Total pages 7
Editor A. Fenton
N. Panay
Place of publication London, United Kingdom
Publisher Informa Healthcare
Collection year 2011
Language eng
Subject C1
920502 Health Related to Ageing
920507 Women's Health
111402 Obstetrics and Gynaecology
Formatted abstract
Setting: Hormone therapy used for the management of postmenopausal symptoms in older women appears to result in variable effects on cognitive function, depending on study design, subjects, tests used, and types of therapy.

Objective: To determine the effects of estrogen-only and estrogen plus progestogen preparations on cognitive performance (cognitive status, general and working memory) when taken ‘early’ and ‘late’ from the onset of menopause.

Method:
The study consisted of 410 women who were participants in a longitudinal study, first recruited at age 40–80 years. They were tested for change over 5 years as an observational cohort by the Mini-Mental State Examination, National Adult Reading Test and the Wechsler Memory Scale Version 3. Cognitive decline, measured by age-adjusted scores, was defined as ≥10% negative change in each individual woman.

Results:
Controlling for age and lifestyle factors, and using the criterion of decrease in score ≥10% over 5 years for ‘cognitive decline’, ‘early start’ of hormone therapy (<3 years from menopause) was strongly associated with reduction in risk by the Mini-Mental State Examination (estrogen-only preparation, p = 0.005) but with increase in risk for general memory (with estrogen plus progestogen preparation, p = 0.02). Overall, there were no major effects on subgroups with type/timing of hormone therapy in relation to testing for a negative change in cognitive function.

Conclusion:
‘Early start’ of estrogen-only hormone therapy was associated with reduced risk of global cognitive decline, and ‘early start’ estrogen-only and estrogen/progestogen hormone therapies showed increased risks of general memory decline. Even though this study did not have the power to discriminate between minor and mixed effects, it suggests that cognitive effects of hormone therapies may be mixed, depending on cognitive domain and timing of use/type of preparation.
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: 2010 Higher Education Research Data Collection
ERA 2012 Admin Only
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 8 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 31 Mar 2010, 16:07:15 EST by Denise Wilson on behalf of Medicine - Princess Alexandra Hospital